15December

Ozempic® (semaglutide) recommended for approval by the European regulatory autho ... Read more

07December

Tresiba® reduces hypoglycaemia regardless of blood sugar level ... Read more

07December

Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 ... Read more

06December

Interim results of first-ever global survey show people with type 2 diabetes und ... Read more

15December

Ozempic® (semaglutide) recommended for approval by the European regulatory autho ... Read more

11December

Novo Nordisk A/S - Share repurchase programme ... Read more

05December

Ozempic® (semaglutide) approved in the US ... Read more

04December

Novo Nordisk A/S - Share repurchase programme ... Read more

01January

Silent period,

01February

Financial statement for the full year of 2017,

01April

Silent period,

02May

Financial statement for the first three months of 2018,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Capital Markets Day 2017 


Click here to find further information

 
Ozempic® US approval


Link to conference call and presentation



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


Semaglutide AdCom


Semaglutide AdCom conference call and presentation